A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

NCT07139548 · Not yet recruiting

Last updated 2026-05-28

This clinical trial is testing the safety and effectiveness of the experimental drug RAY1225 compared to semaglutide when added to standard diabetes medications in adults with type 2 diabetes.

Status Not yet recruiting Approved but enrollment has not started.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 600 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2025-08 · est. completion 2026-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT07139548 ↗

Description as written by the study sponsor.

The reason for this study is to compare the effect of the study drug RAY1225 to semaglutide on blood sugar levels in participants with type 2 diabetes.

Treatments tested

RAY1225 Drug

Administered SC
Semaglutide Drug

Administered SC

Main thing measured	Change From Baseline in Hemoglobin A1c (HbA1c) (6 mg and 9 mg)
Sponsor	Guangdong Raynovent Biotech Co., Ltd
Conditions studied	T2DM
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07139548 ↗